{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T18:12:50Z","timestamp":1699985570382},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To determine the response rate and toxicity of docetaxel when administered as a 60 mg\/m<jats:sup>2<\/jats:sup> dose by 1 hr intravenous (IV) infusion weekly\u2009\u00d7\u20093 weeks in children with relapsed acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Patients who were under the age of 22\u2010year\u2010old at the time of the original ALL or AML diagnosis and in a second relapse were accrued from August 2002 to May 2005 for this Children's Oncology Group (COG) phase 2 study (ADVL0023). Ten patients with ALL and two patients with AML were enrolled.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no complete or partial responses observed. The most common grade 3 or 4 toxicities were hematologic followed by febrile neutropenia. One patient developed a dose limiting elevation in serum bilirubin, but no other significant hepatotoxicity was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Docetaxel was not effective therapy for children with relapsed ALL at the dose and schedule tested. Pediatr Blood Cancer 2008;50:533\u2013536. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.21313","type":"journal-article","created":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T22:48:26Z","timestamp":1186008506000},"page":"533-536","source":"Crossref","is-referenced-by-count":2,"title":["Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: A Children's Oncology Group report"],"prefix":"10.1002","volume":"50","author":[{"given":"Janet L.","family":"Franklin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nita L.","family":"Seibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Krailo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Reaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,9]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.1995.13.10.2643","article-title":"Pazdur: Docetaxel","volume":"12","author":"Cortes JE","year":"1995","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_3_2","first-page":"4845","article-title":"Experimental antitumor activity of Taxotere (RP 56976,NSC 628503), a Taxol analogue","volume":"51","author":"Bissery MC","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(95)90030-6"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.4.288"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504133321507"},{"key":"e_1_2_5_7_2","unstructured":"RP 56976: Investigator's Brochure V 5.0 Rhone\u2010Poulene Rorer 1997."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(05)81474-3"},{"key":"e_1_2_5_9_2","first-page":"602","article-title":"Apoptosis induced by antimetabolites, taxanes, or asparaginase in vitro depends on the p53 status of leukemic cells. Abstr #4094","volume":"89","author":"Nandy P","year":"1998","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_10_2","first-page":"377","article-title":"Combination regimens of fludarabine and ara\u2010C followed by taxanes (docetaxel and paclitaxel) against human leukemic T\u2010cell lines, CEM\/O and CEM\/ara\u2010C\/7A. Abstr # 2573","volume":"37","author":"Kwock R","year":"1996","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.1998.16.3.907","article-title":"In vitro cytotoxicity of docetaxel in childhood acute leukemias","volume":"16","author":"Consolini R","year":"1998","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_12_2","first-page":"1361","article-title":"The combination regimen of Idarubicin and Taxotere is effective against human drug\u2010resistant leukemic cell lines","volume":"22","author":"Majlessipour F","year":"2002","journal-title":"Anticancer Res"},{"key":"e_1_2_5_13_2","first-page":"2327","article-title":"Increased p21\/WAF\u20101 and p53 protein levels following sequential three drug combination regimen of Fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells","volume":"18","author":"Avramis VI","year":"1998","journal-title":"Anticancer Res"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.23.1781"},{"key":"e_1_2_5_15_2","first-page":"1037","article-title":"Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as short intravenous infusion","volume":"53","author":"Extra JM","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_5_16_2","first-page":"523","article-title":"Phase I and pharmacokinetic study of Taxotere (RP56976) administered as a 24\u2010hour infusion","volume":"53","author":"Bissett D","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.7.1458"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.5.950"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1200\/JCO.1998.16.1.159","article-title":"Phase I study of Docetaxel with concomitant thoracic radiation therapy","volume":"16","author":"Maurer AM","year":"1998","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2164"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1538"},{"key":"e_1_2_5_22_2","first-page":"733","article-title":"Pediatric phase I trial of Docetaxel (D) with G\u2010CSF: A collaborative Pediatric Branch, NCI and Children's Cancer Group trial","volume":"5","author":"Seibel NL","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21779"},{"key":"e_1_2_5_24_2","first-page":"3","article-title":"Preclinical evaluation of docetaxel (Taxotere)","volume":"22","author":"Lavelle F","year":"1995","journal-title":"Sem Oncol"},{"key":"e_1_2_5_25_2","first-page":"2281","article-title":"Taxotere and Vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild\u2010type and drug\u2010resistant human leukemia T\u2010cell lines","volume":"21","author":"Avramis IA","year":"2001","journal-title":"Anticancer Research"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2179"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21313","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T19:57:12Z","timestamp":1696881432000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.21313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1002\/pbc.21313"],"URL":"https:\/\/doi.org\/10.1002\/pbc.21313","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,9]]}}}